Published By : 03 Jan 2018 | Published By : QYRESEARCH
Various types of pancreatic cancers are characterized by low survival rates and significant morbidity in population world over, leading to death within a year of the disease being diagnosed. A notably aggressive type—pancreatic ductal adenocarcinoma (PDAC)—is marked by its heterogeneity and hence hard to treat. Almost all targeted therapies developed in the past decade rely on RNA interference-based therapeutic strategies that inhibit the expression specific cancer-promoting genes.
Small interfering RNA (siRNA) has emerged as a popular candidate in several clinical trials. However, late phase trials suggest its limited efficacy. Recent studies investigating potent tools to improve the survival rates in PDAC highlight the regulation of microRNA (miRNA) as a promising therapeutic strategy. A new study at American Friends of Tel Aviv University by a team of researchers coming from a number of institutes investigating the cancer pathogenesis on mouse model found the inverse correlation between a known oncogene, cancer-promoting gene, and miRNA expression in extending the survival rate. Of note, miRNAs are increasingly dysregulated in various types of pancreatic cancer found in humans.
Novel nanomedicine used Combination of microRNA and siRNA
The details of the study is published online on January 2, 2018 in the journal Nature Communications. Similar genetic patterns were observed in humans when RNA profiling was done and researchers analyzed samples from people with pancreatic cancer and found their findings to be useful for humans. The study could prove as a basis for developing a potential strategy to improve therapeutic efficacy for PDAC and similar aggressive types of cancer using a combination of drugs.
Nanocarrier-Induced Modulation Safe and Effective in Delaying Cancer Progression
For the study, the researchers designed a biodegradable nanoparticle to deliver the required genes at the tumor sites, without affecting the surrounding healthy cells. The used nanocarrier could specifically and effectively transport the miR-34a, an attractive tumor suppressor in PDAC patients to the cancer site. They also chose to transport polo-like kinases (PLK)-based siRNA as the potential target gene. The results show a proper combination of miR-34a and PLK1-siRNA could balance the molecular defects observed in PDAC patients. The scientists concluded that nanocarrier-induced modulation of PLK1 and miR-34a could improve therapeutic response in pancreatic cancer.